Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20134991 | 0.84 | TP53 (0.48) | NPC1RAB9AKMT2ATP53LMNA | |
| SCHEMBL20474745 | 0.84 | NPC1 (0.61) | NPC1RAB9APTPN1ALDH1A1L3MBTL1 | |
| SCHEMBL26045299 | 0.83 | NPC1 (0.58) | NPC1RAB9AHTR7PLOD2PTPN1 | |
| SCHEMBL26584242 | 0.83 | NPC1 (0.82) | NPC1RAB9AHTR7PLOD2PTPN1 | |
| SCHEMBL28417256 | 0.82 | KMT2A (0.58) | NPC1RAB9ACES2CES1CTNNB1 | |
| SCHEMBL2274229 | 0.82 | GSK3B (0.53) | NPC1RAB9APTPN1HSD11B1CES2 | |
| SCHEMBL22624012 | 0.82 | NPC1 (0.62) | NPC1RAB9AHTR7PLOD2PTPN1 | |
| SCHEMBL30144823 | 0.82 | MMP1 (0.62) | PTPN1HSD11B1CES2CES1ALDH1A1 | |
| SCHEMBL28422432 | 0.82 | GSK3B (0.53) | NPC1RAB9AHSD11B1CES2CES1 | |
| SCHEMBL2201165 | 0.82 | TDP1 (0.57) | NPC1RAB9APTPN1HSD11B1CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109810573-A | Inorganic nano material prints ink and its preparation method and application | TCL集团股份有限公司 | 2019-05-28 | — | — | CN | claimed |
| US-11773070-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-03 | — | — | US | disclosed |
| EP-3661517-B1 | DIHYDROOXADIAZINONES | BAYER AG (DE) | 2023-09-13 | — | — | EP | disclosed |
| US-20230017200-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-19 | — | — | US | disclosed |
| US-20220396554-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-15 | — | — | US | disclosed |
| US-20200369633-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-26 | — | — | US | disclosed |
| WO-2020157188-A1 | DIHYDROOXADIAZINONES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-06 | — | — | WO | disclosed |
| EP-3661517-A1 | DIHYDROOXADIAZINONES | Bayer Aktiengesellschaft (DE) | 2020-06-10 | — | — | EP | disclosed |
| CN-108707067-B | Preparation method of 1-aryl-4, 4, 4-trifluoro-1-butanone compound | 大连理工大学 | 2020-06-02 | — | — | CN | disclosed |
| CN-111212647-A | Dihydroxadiazinones | 拜耳股份有限公司 | 2020-05-29 | — | — | CN | disclosed |
| WO-2019025562-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | disclosed |
| US-7863444-B2 | 4-aminopyrrolopyrimidines as kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-01-04 | — | — | US | disclosed |
| CN-1326457-A | 4-aminopyrrolopyrimidines as kinase inhibitors | BASF AG (DE) | 2001-12-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369633-A1 | DIHYDROOXADIAZINONES | CCND2, CCNT2, CCND1 | NPC1 2167/4885RAB9A 2129/4885HTR7 3858/4885 |
| US-11773070-B2 | Dihydrooxadiazinones | CCND2, DPYD, DHPS | NPC1 1710/4885RAB9A 2105/4885HTR7 3926/4885 |
| US-20220396554-A1 | DIHYDROOXADIAZINONES | CCND2, DPYD, DHPS | NPC1 1710/4885RAB9A 2105/4885HTR7 3926/4885 |
| US-20230017200-A1 | DIHYDROOXADIAZINONES | CCND2, CCNT2, CCND1 | NPC1 2167/4885RAB9A 2129/4885HTR7 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.